FDA-cleared profile

Caption Interpretation Automated Ejection Fraction Software

Caption Health · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.

Clinical role
Automated clip selection and left-ventricular ejection-fraction estimation for clinician review.
Images and patients
Ultrasound · Heart; left ventricle; adult cardiac evaluation
Key limitation
Keep in mind: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Heart; left ventricle; adult cardiac evaluation Input: Previously acquired adult transthoracic cardiac ultrasound images from supported apical four-chamber, apical two-chamber, or parasternal long-axis views.
  • Who uses it?Intended users: Clinicians and trained echocardiography professionals performing adult cardiac evaluation.
  • What does the software produce?Output: Left-ventricular ejection-fraction estimate expressed as a percentage, confidence information, selected clips, and reviewable results.
  • What is its most important limitation?Key limitation: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.

Clinical takeaway. Clinical role: Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification at unit, module, and system integration levels; a Clip Annotator study against a panel of expert readers, with PPV point estimates greater than 97% and sensitivity point estimates greater than 90% for view and imaging mode identification; and a pivotal clinical investigation whose primary endpoint, RMSD of AutoEF versus the reference method for the best available view combination, met predetermined acceptance criteria; AP2 and PLAX view results did not. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Caption Interpretation Automated Ejection Fraction Software processes previously acquired adult transthoracic cardiac ultrasound images, stores and manipulates images, and measures them using an ultrasound device, personal computer, or compatible DICOM-compliant PACS to provide an automated estimate of left-ventricular ejection fraction that may assist a clinician in cardiac evaluation.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Automated clip selection and left-ventricular ejection-fraction estimation for clinician review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Previously acquired adult transthoracic cardiac ultrasound images from supported apical four-chamber, apical two-chamber, or parasternal long-axis views.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Left-ventricular ejection-fraction estimate expressed as a percentage, confidence information, selected clips, and reviewable results.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Adult transthoracic echocardiography workflows using a compatible ultrasound device, computer, or DICOM PACS.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Clinicians and trained echocardiography professionals performing adult cardiac evaluation.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification at unit, module, and system integration levels; a Clip Annotator study against a panel of expert readers, with PPV point estimates greater than 97% and sensitivity point estimates greater than 90% for view and imaging mode identification; and a pivotal clinical investigation whose primary endpoint, RMSD of AutoEF versus the reference method for the best available view combination, met predetermined acceptance criteria; AP2 and PLAX view results did not. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Specifically, software verification was conducted at unit, module, and system integration levels." … "A Clip Annotator study verified the ability of the software to receive, annotate and select clips for interpretation by the AutoEF Calculation Service. Results of the Clip Annotator were compared to evaluation by a panel of expert readers.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification at unit, module, and system integration levels; a Clip Annotator study against a panel of expert readers, with PPV point estimates greater than 97% and sensitivity point estimates greater than 90% for view and imaging mode identification; and a pivotal clinical investigation whose primary endpoint, RMSD of AutoEF versus the reference method for the best available view combination, met predetermined acceptance criteria; AP2 and PLAX view results did not. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Specifically, software verification was conducted at unit, module, and system integration levels." … "A Clip Annotator study verified the ability of the software to receive, annotate and select clips for interpretation by the AutoEF Calculation Service. Results of the Clip Annotator were compared to evaluation by a panel of expert readers.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
90%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Clip Annotator positive predictive value

0.97 proportion lower bound

  • EndpointObserved PPV point estimate across imaging modes and views
  • PopulationClip Annotator study compared with expert readers
  • Tested versionCaption Interpretation Automated Ejection Fraction Software configuration described in K200621

Clip Annotator sensitivity

0.9 proportion lower bound

  • EndpointObserved sensitivity point estimate across imaging modes and views
  • PopulationClip Annotator study compared with expert readers
  • Tested versionCaption Interpretation Automated Ejection Fraction Software configuration described in K200621

K200621 FDA evidence package for Caption Interpretation Automated Ejection Fraction Software

  • DesignFDA 510(k) Clip Annotator study and pivotal clinical investigation comparing AutoEF to conventional ejection-fraction calculation methods.
  • PopulationHeart; left ventricle; adult cardiac evaluation
  • Scopeexact submission
  • Tested versionCaption Interpretation Automated Ejection Fraction Software configuration described in K200621
  • IndependenceSponsor or vendor study

K200621

The FDA summary reports thresholded PPV and sensitivity point estimates and qualitative statements about RMSD acceptance criteria, but does not expose all study counts in the public decision material.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
1 exact-submission FDA recall record matched K200621 in the 2026-09-02 openFDA snapshot. Confirm affected model, version, units, correction, and current manufacturer instructions locally. FDA recall Z-2111-2021 affected Caption AI version 1.2.0. Unintended video frames could produce incorrect automated ejection-fraction and image-quality-score estimates. FDA lists the recall as terminated.
  • FDA source
  • Exact product version
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-2111-2021

Terminated

2021-05-19

Exact version match to Caption AI 1.2.0. This was a software-output issue involving AutoEF and IQS estimates.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Previously acquired adult transthoracic cardiac ultrasound images from supported apical four-chamber, apical two-chamber, or parasternal long-axis views.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) K200621: Caption Interpretation Automated Ejection Fraction Software

  2. Routing

    Source context, not route validation: The FDA package describes use on an ultrasound device, personal computer, or compatible DICOM-compliant PACS and output of an ejection-fraction estimate with confidence information for clinician viewing.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) K200621: Caption Interpretation Automated Ejection Fraction Software

  3. AI processing

    Source context, not route validation: The FDA labeling describes deployment on an ultrasound device, personal computer, or compatible DICOM-compliant PACS; current site topology, hosting responsibility, availability, security, and service remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) K200621: Caption Interpretation Automated Ejection Fraction Software

  4. Returned objects

    Source context, not route validation: Left-ventricular ejection-fraction estimate expressed as a percentage, confidence information, selected clips, and reviewable results.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) K200621: Caption Interpretation Automated Ejection Fraction Software

  5. Viewer/worklist/report

    Unresolved route: Left-ventricular ejection-fraction estimate expressed as a percentage, confidence information, selected clips, and reviewable results.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) K200621: Caption Interpretation Automated Ejection Fraction Software

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA labeling describes deployment on an ultrasound device, personal computer, or compatible DICOM-compliant PACS; current site topology, hosting responsibility, availability, security, and service remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA package describes use on an ultrasound device, personal computer, or compatible DICOM-compliant PACS and output of an ejection-fraction estimate with confidence information for clinician viewing.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own press release announces the acquisition of Caption Health, Inc., and Caption AI is sold as a GE HealthCare product (Vscan Air Caption AI page on gehealthcare.com). Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only clinicians and trained echocardiography professionals performing adult cardiac evaluation should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K200621 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K200621 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The FDA labeling describes deployment on an ultrasound device, personal computer, or compatible DICOM-compliant PACS; current site topology, hosting responsibility, availability, security, and service remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes use on an ultrasound device, personal computer, or compatible DICOM-compliant PACS and output of an ejection-fraction estimate with confidence information for clinician viewing.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K200621 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to adult transthoracic cardiac ultrasound and supported views; clinicians must review clips and accept or reject automated estimates before clinical use.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. automated echocardiography ejection-fraction software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K200621
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Heart; left ventricle; adult cardiac evaluation
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-07-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The locked snapshot contains no PubMed or ClinicalTrials.gov candidates for K200621; no evidence was promoted or quarantined. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K200621: Caption Interpretation Automated Ejection Fraction Software

    U.S. Food and Drug Administration - Published 2020-07-22 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Caption Interpretation Automated Ejection Fraction Software model card (K200621)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. FDA recall Z-2111-2021: Version: 1.2.0 (1.2.0+85ela410) Caption Health, Caption AI, Ultrasound Imaging System Application Software (GMDN: 40873), UDI: (01)00860003586303(10)1.2.0)

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  6. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  7. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  8. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  9. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K200621 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253535

Ligence Heart

Ligence Uab

Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2026-02-27
FDA-cleared K252235

PVAD IQ Software

Ultrasight, Ltd.

Authorized purpose: PVAD IQ supports qualified-physician clinical decision support by identifying the aortic annulus and PVAD inlet, calculating their mean distance, and identifying clips acceptable for this measurement.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2025-12-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history